Antifungal agent 18

Antifungal agent 18 is a novel antifungal agent for the treatment of fungal infection.

Antifungal agent 6 shows antifungal activity.

Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg/mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.

Compound 24f, an antifungal agent also known as 'Antifungal agent 85,' demonstrates potent antibacterial properties, exhibiting minimum inhibitory concentration (MIC) values ranging from 2.5 to 10 μM against diverse Gram-positive bacteria [1].

Compound 18 (compound 8b), a nitrofuran derivative, exhibits potent in vitro trypanocidal activity, with an IC50 value of 0.03 μM [1].

Compound 3i (Antifungal agent 63) is a fungicidal agent displaying potent activity against Fusarium oxysporum f.sp. cucumerinum and has applications in antiviral and fungicidal research [1].

Antifungal agent 77 (Compound 13h) exhibits not only antifungal properties, but also effective insecticidal activity against Mythimna separata, Helicoverpa armigera, Ostrinia nubilalis, and Spodoptera frugiperda, with mortality rates of 30%, 25%, 40%, and 25% respectively at a concentration of 500 μg/mL. Additionally, this compound demonstrates toxicity in zebrafish embryos with an LC50 of 2.43 μg/mL [1].

Antioxidant Agent-18 (Compound 5), a flavonol glycoside derived from Ginkgo biloba, exhibits antioxidant properties through its ability to scavenge DPPH radicals (IC50: 15.8 μM) and reduce cytochrome c (IC50: 14.7 μM).

Antifungal agent 81(G22) exhibits excellent antifungal properties, demonstrating an in vitro IC50 value of 0.48 mg/L against Valsa mali. Moreover, it also shows robust in vivo protection against V. mali at a concentration of 40 mg/L [1].

Antifungal agent 82 (compound G34) demonstrates outstanding in vitro antifungal efficacy against Valsa mali, exhibiting an EC50 value of 0.57 μg/mL, and has also shown excellent in vivo protective effects at a concentration of 40 μg/mL [1].

Compound 3a (Antifungal agent 62) exhibits potent fungicidal properties, particularly against Fusarium oxysporum f.sp. cucumerinum, and is utilized in antiviral and fungicidal research [1].

Antifungal agent 75 (compound 6r) effectively combats Candida albicans by substantially inhibiting biofilm formation, enhancing cell membrane permeability, diminishing membrane ergosterol levels, impairing membrane structure, and compromising cell structural integrity, thus demonstrating exceptional antifungal activity [1].

Antifungal agent 28 (compound 18) is a selective and potent antifungal agent that disrupts mature Candida biofilms and inhibits pathogenic strains of Candida albicans and non-Candida albicans, including fluconazole-resistant strains. Inhibitory effect.

Compound 5k (Antiproliferative Agent-18) is an antiproliferative agent that exhibits moderate antibacterial and antifungal activities [1].

Antifungal agent 50 exhibits minimum inhibitory concentrations (MICs) ranging from less than 0.063 to 1 μg/mL [1].

Antifungal Agent 61 (Compound 38) is an antifungal agent that inhibits V. mali, with an EC50 value of 0.50 mg/L. This compound impedes V. mali's growth by inducing cell deformation and contraction, diminishing intracellular mitochondrial count, thickening the cell wall, and enhancing cell membrane permeability [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane. It demonstrates potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Compound 9 (Antifungal agent 67), an imidazole class antifungal, exhibits efficacy against Candida and possesses a CC50 value of 33.6 μM in neonatal rat cardiomyoblasts [1].

Antifungal agent 68 (compound 10) effectively combats fungal infections caused by Candida and Cryptococcus gattii through the inhibition of ergosterol biosynthesis, likely via interaction with lanosterol 14α-demethylase (CYP51). It is proposed that the imidazole ring of antifungal agent 68 interacts with the heme group of CYP51 [1].

Antifungal Agent 29 (compound 9d) is a potent, selective, and non-toxic agent effective against Cryptococcus neoformans, exhibiting an MIC of ≤0.23 μM [1].

Pradimicin A derivative 26 exhibits antifungal, antiviral, and antiparasitic properties by attaching to d-mannose (Man)-rich glycans in pathogenic organisms [1].

Antifungal agent 51 (5c) exhibits potent antifungal activity against Candida albicans FDC 151, Candida parapsilosis ATCC 22019, and Candida tropicalis FDC 138, with a minimum inhibitory concentration (MIC) value of less than 0.063 μg/mL. It demonstrates low toxicity to cells and no carcinogenicity [1].

Antifungal agent 54 (compound A05) serves as a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits considerable activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal agent 17 showed good antifungal activity against B. cinerea (EC50: 2.86 μg/mL).

Antifungal agent 19 shows the potent antifungal activity ( EC 50 = 0.72 μM).

Antifungal agent 24 (Compound 6) is an antifungal agent that inhibits Candida albicans (MIC: 0.03 μg/ml).

Antifungal agent 33 (compound 4e) is a potent antifungal agent with significant antifungal activity against Candida albicans (MIC: 16 μg/ml). (IC50: 0.19 μg/ml).

Antifungal agent 25 is an effective, broad-spectrum, metabolically stable antifungal agent in vivo. antifungal agent 25 exhibits antifungal effects against both Candida albicans and fluconazole-resistant Candida albicans.

Antifungal agent 49 (Example 112) exhibits activity against Cryptococcus neoformans, demonstrating a minimum inhibitory concentration (MIC) of 49 μM [1].

Antiparasitic agent-18 (compound 3a) exhibits potent and selective antiprotozoal activity, demonstrating effective inhibition of T. brucei (EC 50 =0.4 µM), T. cruzi (EC 50 =0.21 µM), and L. donovani (EC 50 =0.26 µM) [1].

Compound 5d (Antifungal Agent 65) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is utilized in antiviral and fungicidal research [1].

Antifungal Agent 70 (Compound 13), a dihydroeugenol-imidazole, exhibits efficacy against multi-resistant Candida auris with a minimum inhibitory concentration (MIC) of 36.4 μM, demonstrating notable antifungal activity [1].

Antifungal agent 74 (compound 3c), is a potent substance that exhibits excellent fungicidal activity against C. arachidicola and R. solani, functioning by disrupting steroid biosynthesis and ribosome biogenesis in eukaryotes [1].

Compound 5c (Antifungal agent 64) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is applicable for research in antiviral and fungicidal domains [1].

Antibacterial agent 18, a multi-arm AIE molecule, demonstrates efficacy against both Gram-positive and Gram-negative bacteria. Antibacterial agent 18 functions by conjugating with the cell wall of bacteria with rigid arm configuration, thereby interfering with the sugar and peptide processes essential for cell wall turning. This mechanism inhibits or eradicates bacterial growth[1].

Antifungal agent 52 (compound 6c), a tetrazole derivative, inhibits ergosterol synthesis and significantly exhibits antifungal activity against Candida albicans by affecting the permeabilization of the C. albicans sessile cell membrane [1].

Compound 2f (Antifungal Agent 46) is a potent antifungal that inhibits Ras signaling by targeting protein farnesyltransferase [1].

Antiviral agent 18 (Compound 5) shows good antiviral activity against murine norovirus. Antiviral agent 18 is an anti-infection agent that has the potential in infectious and malignant diseases research [1].

Anti-inflammatory agent 18 inhibits NO activity (IC50: 15.94 μM) and has an inhibitory effect on the late inflammatory response induced by HMGB1 and can be used to study late inflammatory diseases such as coronavirus disease (COVID-19), sepsis, etc.

Antifungal agent 14 demonstrates potent broad-spectrum antifungal activity, effectively targeting a variety of fungal strains with exceptional minimum inhibitory concentration values.

Antifungal agent 38 is a geterocyclic disulfide with antifungal and antibacterial activity. Antifungal agent 38 induces the shrinkage of hyphae, disrupts the integrity of the plasma membrane, and causes the damage and leakage of cell contents [1].

Antifungal agent 66 (compound 10) exhibits broad-spectrum antifungal activity against seven phytopathogenic fungal mycelia and significant inhibitory effects on the spores of B. cinerea, with an IC50 value of 47.7 μg/mL [1].

Antifungal agent 69 (compound 13), a eugenol-imidazole derivative, demonstrates targeted activity against Candida albicans with a minimum inhibitory concentration (MIC) of 4.6 μM, while exhibiting negligible cytotoxicity. This compound disrupts ergosterol biosynthesis, contributing to its antifungal efficacy [1].

Antifungal agent 11 has a good antifungal effect.

Antifungal agent 43 is an antifungal agent that exhibits antifungal effect by inhibiting biofilm formation. antifungal agent 43 shows low toxicity to human cancer cell lines.

Antifungal agent 27 (compound 7) is a chemical compound possessing antifungal properties. It exhibits moderate antibacterial activity and weak antifungal activity against MRSA and C. albicans SS5314, with minimal inhibitory concentration (MIC) values of 8 and 32 μg/mL, respectively [1].

Antifungal agent 2 is a broad-spectrum fungal inhibitor that inhibits the growth of pertinent species of Cryptococcus, Candida, and Aspergillus at a concentration as low as 0.5 μg/mL.

Antifungal agent 39 (Compound 9h) is a broad-spectrum antifungal agent.

Antifungal Agent 53 (A03), a potent Candida albicans CYP51 inhibitor, exhibits antifungal activity by preventing fungi biofilm formation and demonstrates good safety [1].

Antifungal agent 55 (Compound A07) effectively inhibits Fluconazole-resistant strains of Candida albicans, demonstrating greater efficacy than Miconazole. It exhibits minimum inhibitory concentrations (MIC) values ranging from 0.25-1 μg/mL [1].